Hans-Peter Vornlocher

This inventor holds 53 USPTO granted patents and 31 published patent applications, plus 8 CIPO patents and 21 EPO patents, primarily in RNA Interference (CPC class C12N). Top assignees: Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Mpeg La, L.l.c.. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Peter Vornlocher. Retrieved from https://idiyas.com/inventor/hans-peter-vornlocher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 31)

% Patents Active = 79.2

CIPO Patents = 8 (Patent Applications = 4)

EPO Patents = 21 (Patent Applications = 17)

Average Co-Inventor Count = 3.4

ph-index = 15

Forward Citations = 1,245(Granted Patents)

Forward Citations (Not Self Cited) = 1,209(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Cambridge, MA (US) (2012 - 2015)
Bayreuth, DE (2007 - 2021)
Kulmbach, DE (2021 - 2023)

Company Filing History:

39 out of 466

Alnylam Pharmaceuticals, Inc.

patents

4 out of 102

Arrowhead Pharmaceuticals, Inc.

Giuliani International Limited

patents

6. 1 out of 16

Mina Therapeutics Limited

Scripps Research Institute

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Oligonucleotides

RNAi

Gene Expression

Nuclease Resistant

Glycoconjugates

Double-Stranded RNA

Viral Replication

ApoB Modulation

Anti-Apoptotic Genes

Huntingtin Gene

TGF-Beta

HPV Treatment

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378551 - Multimeric oligonucleotides having decreased kidney clearance (2025-08-05),

2. 11767531 - Defined multi-conjugates oligonucleotides (2023-09-26),

3. 11352629 - Defined multi-conjugate oligonucleotides (2022-06-07),

4. 11208662 - RNAi inhibition of alpha-ENaC expression (2021-12-28),

5. 11078484 - Multimeric oligonucleotides having decreased kidney clearance (2021-08-03),

6. 10912790 - C/EBP alpha saRNA compositions and methods of use (2021-02-09),

7. 10544418 - RNAi inhibition of alpha-ENaC expression (2020-01-28),

8. 10501740 - Compositions and methods for inhibiting expression of factor V (2019-12-10),

9. 10131907 - Glycoconjugates of RNA interference agents (2018-11-20),

10. 9914927 - RNAi inhibition of alpha-ENaC expression (2018-03-13),

11. 9476052 - RNAi inhibition of alpha-ENaC expression (2016-10-25),

12. 9441225 - Compositions and methods for inhibiting expression of factor V (2016-09-13),

13. 9187747 - RNAi modulation of ApoB and uses thereof (2015-11-17),

14. 9057069 - Compositions and methods for inhibiting expression of Eg5 gene (2015-06-16),

15. 8993746 - Nuclease resistant double-stranded ribonucleic acid (2015-03-31),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees and patents, I can provide you with the requested article about inventor Hans-Peter Vornlocher.

Title:

Exploring the Innovations of Inventor Hans-Peter Vornlocher

Introduction:

Hans-Peter Vornlocher, a prolific inventor based in Bayreuth, Germany, has made significant contributions to the field of oligonucleotide research. With an impressive portfolio of 52 patents, Vornlocher is known for his groundbreaking work in developing defined multi-conjugate oligonucleotides with unique properties and applications.

Latest Patents:

Among his latest patents is the development of defined multi-conjugate oligonucleotides that exhibit predetermined sizes and compositions. These innovative oligonucleotides, such as multi-conjugate siRNA molecules, demonstrate enhanced intracellular delivery and multi-gene silencing effects. Vornlocher's work has introduced novel synthetic intermediates and methods for synthesizing these oligonucleotides, which hold promise for gene expression regulation, medical treatments, and cellular phenotype modifications.

Career Highlights:

Throughout his career, Hans-Peter Vornlocher has been associated with leading pharmaceutical companies engaged in nucleic acid therapeutics research. Notably, he has made significant contributions to Alnylam Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc., where his expertise has influenced the development of innovative oligonucleotide-based therapies.

Collaborations:

Vornlocher's collaborative efforts have been instrumental in his success as an inventor. Working alongside talented individuals such as Philipp Hadwiger and Pamela Tan, he has synergized with fellow researchers to drive forward cutting-edge projects in oligonucleotide science. These collaborations have fostered a culture of innovation and excellence in Vornlocher's work.

Conclusion:

In conclusion, Hans-Peter Vornlocher's dedication to advancing oligonucleotide research has positioned him as a pioneering figure in the field of nucleic acid therapeutics. With a robust patent portfolio and a history of fruitful collaborations, Vornlocher continues to push the boundaries of innovation, shaping the future of genetic medicine and biotechnology.

If you require further information or have any specific inquiries, feel free to reach out.

Profile summary based on public USPTO records.